UBS raised the firm’s price target on Insmed (INSM) to $133 from $124 and keeps a Buy rating on the shares. UBS expects a clean PDUFA next week, with the focus turning to launch and Phase 2 brenso readouts, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed Positioned for Growth: Buy Rating Backed by Brensocatib Launch and Strong Pipeline
- Insmed Reports Strong Growth and Strategic Advances
- Insmed’s Strong Financial Performance and Promising Drug Pipeline Drive Buy Rating
- Insmed reports Q2 EPS ($1.70), consensus ($1.31)
- Insmed backs 2025 global Arikayce revenues view $405M-$425M